XJPX
6039
Market cap82mUSD
Oct 09, Last price
1,005.00JPY
1D
0.00%
1Q
-5.37%
Jan 2017
-35.58%
IPO
-50.74%
Name
Japan Animal Referral Medical Center Co Ltd
Chart & performance
P/E
15.59
P/S
2.10
EPS
64.48
Div yield, %
0.73%
Shrs. gr., 5y
1.18%
Rev. gr., 5y
16.81%
Revenues
6.19b
+17.33%
Net income
833m
+59.97%
CFO
1.40b
+1.71%
Dividend
Mar 30, 202713 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Japan Animal Referral Medical Center Co., Ltd. operates a network of animal medical facilities across Japan, specializing in delivering advanced veterinary care for dogs and cats. These comprehensive centers boast an extensive range of specialized departments, from cardiology, respiratory, urology, and gastroenterology to oncology, neurology, orthopedics, ophthalmology, diagnostic imaging, and anesthesiology. Beyond direct patient care, the company also offers professional training, encompassing clinical instruction and treatment practices. Furthermore, it actively engages in research and development initiatives, exploring fields such as genetic testing, immunotherapy, and regenerative medicine. The firm, established in 2005, has its headquarters located in Kawasaki, Japan.
Key people
Masami Ooi
Deputy Chief Director of Administration, Director · since 2025
Teruo Hasegawa
Director · since 2018
Hidehiro Hirao
President, Chief Director of Medical Treatment, President of Subsidiary, Representative Director · since 2025
Satoru Matsunaga
Manager of the Neurology, Orthopedics, Anesthesiology, Surgery, and Intensive Care, President of Subsidiary, Director · since 2025
Toshiaki Kobayashi
Independent Director · since 2024
Ikuko Tsubokawa
Independent Director · since 2023
Akihiro Yoshijima
Independent Director · since 2016
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||